Alpha 2.0
Login Register
» Authors » Richard L White

Richard L White

Explore the profile of Richard L White including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 702
Followers 0
Related Specialties
Oncology
General Surgery
General Medicine
Top 10 Co-Authors
Jonathan S Zager
Mohammed Kashani-Sabet
Vernon K Sondak
Jane L Messina
Asim Amin
Dale Han
Barbara Pockaj
Stanley P Leong
John T Vetto
Schlomo Schneebaum
Published In
Ann Surg Oncol
J Surg Oncol
Cancer Immunol Immunother
Am J Surg
Lancet Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies
Beebe K, Eisner J, Guo J, Shibata Y, Davison J, Uronis J, et al.
J Immunol . 2024 May; 213(1):29-39. PMID: 38767437
High-dose (HD) IL-2 was the first immuno-oncology agent approved for treating advanced renal cell carcinoma and metastatic melanoma, but its use was limited because of substantial toxicities. Multiple next-generation IL-2...
2.
Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial
Johnson H, Lin H, Shen Y, Diego E, Krishnamurthy S, Yang W, et al.
JAMA Netw Open . 2023 Sep; 6(9):e2333933. PMID: 37707811
Importance: Patients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials. Objective: To evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfort and...
3.
Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer
Eisner J, Beebe K, Mayhew G, Shibata Y, Guo Y, Farhangfar C, et al.
Cancer Res Commun . 2023 Mar; 2(8):894-903. PMID: 36923304
Significance: Next-generation IL2 agents, designed for improved tolerability over traditional HD-IL2 (aldesleukin), are in clinical development. Retrospective molecular tumor profiling of patients treated with HD-IL2 or anti-PD-1 therapy provides insights...
4.
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial
Kuerer H, Smith B, Krishnamurthy S, Yang W, Valero V, Shen Y, et al.
Lancet Oncol . 2022 Oct; 23(12):1517-1524. PMID: 36306810
Background: Neoadjuvant systemic therapy (NST) for triple-negative breast cancer and HER2-positive breast cancer yields a pathological complete response in approximately 60% of patients. A pathological complete response to NST predicts...
5.
Single surgeon versus co-surgeon bilateral mastectomy: Comparing outcomes and costs based on health economic modeling from the perspective of the hospital system
Hudson L, Reese E, Hecksher A, Schepel C, Trufan S, Cruz A, et al.
J Surg Oncol . 2022 Apr; 126(2):239-246. PMID: 35411951
Introduction: Co-surgeon approach for bilateral mastectomy may lead to shorter operative times and improved outcomes compared with single-surgeon approach, but cost differences remain unclear. Economic models were applied to determine...
6.
An Estimate of Local Failure in the TARGIT-A Trial of Pre-pathology Intraoperative Radiation Therapy for Early Breast Cancer
Ward M, Bentzen S, Fasola C, Khan A, White R, Vicini F, et al.
Int J Radiat Oncol Biol Phys . 2022 Jan; 115(1):73-76. PMID: 35065848
Purpose: TARGIT-A was a pragmatic randomized noninferiority trial including women with early-stage breast cancer treated postlumpectomy with either external beam radiation therapy (EBRT) or 50 kV x-rays delivered intraoperatively with...
7.
Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence-free survival
Subramanian S, Han G, Olson N, Leong S, Kashani-Sabet M, White R, et al.
J Surg Oncol . 2021 Sep; 125(2):229-238. PMID: 34535899
Background And Objectives: The prognostic significance of regression in predicting melanoma recurrences is unknown. We present a large multicenter study correlating regression with recurrence. Methods: The Sentinel Lymph Node Working...
8.
Regression is significantly associated with outcomes for patients with melanoma
Subramanian S, Han G, Olson N, Leong S, Kashani-Sabet M, White R, et al.
Surgery . 2021 Jun; 170(5):1487-1494. PMID: 34120749
Background: The prognostic significance of regression in melanoma is debated. We present a large multicenter study correlating regression with sentinel lymph node metastasis and melanoma-specific survival. Methods: The Sentinel Lymph...
9.
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
Clark J, Curti B, Davis E, Kaufman H, Amin A, Alva A, et al.
J Investig Med . 2021 Feb; PMID: 33542072
High-dose interleukin-2 (HD IL-2) was approved in the 1990s after demonstrating durable complete responses (CRs) in some patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). Patients who...
10.
Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival
Thomas D, Han G, Leong S, Kashani-Sabet M, Vetto J, Pockaj B, et al.
Ann Surg Oncol . 2019 Apr; 26(7):2254-2262. PMID: 31011906
Background: Factors that predict melanoma recurrence after a negative sentinel lymph node biopsy (SLNB) are not well-defined. We evaluated melanoma recurrence patterns, factors prognostic for recurrence, and the impact of...